Clinical trials for genome editing of the human germline — adding, removing, or replacing DNA base pairs in gametes or early embryos — could be permitted in the future, but only for serious conditions under stringent oversight, says a new report.
Clinical trials for genome editing of the human germline — adding, removing, or replacing DNA base pairs in gametes or early embryos — could be permitted in the future, but only for serious conditions under stringent oversight, says a new report.